CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 174 target
Drug / intervention
HS-10241drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05430386
NCT05430386Phase 1Unknown
CompareCT.gov

A Phase Ib Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC.

Jiangsu Hansoh Pharmaceutical Co., Ltd.·interventional·Posted Jun 24, 2022·Updated Feb 14, 2023

In Brief

A Phase 1 clinical trial evaluating HS-10241 for Non Small Cell Lung Cancer. Targeting 174 participants across 1 site.

Detailed Summary

This study is conducted to determine the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-10241 when given together with Almonertinib in patients with EGFRm+ advanced NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 1UnknownOverdue
20222023202420252026
First PostedJun 24, 2022
Enrollment StartJan 5, 2022
Primary CompletionDec 31, 2023
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 4.0 years ago

Interventions

HS-10241drug

Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression. Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy.